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Abstract
Background: Fibrotic interstitial lung disease (ILD) is often associated with poor outcomes, but has few predictors
of progression. Daily home spirometry has been proposed to provide important information about the clinical
course of idiopathic pulmonary disease (IPF). However, experience is limited, and home spirometry is not a routine
component of patient care in ILD. Using home spirometry, we aimed to investigate the predictive potential of daily
measurements of forced vital capacity (FVC) in fibrotic ILD.
Methods: In this prospective observational study, patients with fibrotic ILD and clinical progression were provided
with home spirometers for daily measurements over 6 months. Hospital based spirometry was performed after
three and 6 months. Disease progression, defined as death, lung transplantation, acute exacerbation or FVC decline
> 10% relative was assessed in the cohort.
Results: From May 2017 until August 2018, we included 47 patients (IPF n = 20; non-IPF n = 27). Sufficient daily
measurements were performed by 85.1% of the study cohort. Among these 40 patients (IPF n = 17; non-IPF n = 23),
who had a mean ± SD age of 60.7 ± 11.3 years and FVC 64.7 ± 21.7% predicted (2.4 ± 0.8 L), 12 patients experienced
disease progression (death: n = 2; lung transplantation: n = 3; acute exacerbation: n = 1; FVC decline > 10%: n = 6).
Within the first 28 days, a group of patients had high daily variability in FVC, with 60.0% having a variation ≥5%.
Patients with disease progression had significantly higher FVC variability than those in the stable group (median
variability 8.6% vs. 4.8%; p = 0.002). Cox regression identified FVC variability as independently associated with disease
progression when controlling for multiple confounding variables (hazard ratio: 1.203; 95% CI:1.050–1.378; p =
0.0076).
Conclusions: Daily home spirometry is feasible in IPF and non-IPF ILD and facilitates the identification of FVC
variability, which was associated with disease progression.
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Background
Interstitial lung disease (ILD) is a term for a group of
conditions including idiopathic pulmonary fibrosis (IPF).
Fibrotic ILD such as IPF are all characterized by fibrotic
destruction of the lung parenchyma but with great het-
erogeneity with respect to clinical presentation and
prognosis. Furthermore, the individual clinical course of
fibrotic ILD can be highly variable, presenting as stable,
slowly progressive or rapidly progressive disease [1]. Al-
though therapeutic and diagnostic options for ILD have
improved in recent years, the prognosis, especially for
IPF, still remains poor [2]. Within a few years of diagno-
sis, patients can experience dyspnea, hypoxemia and re-
spiratory failure [3]. Patients with progressive, fibrotic
ILD suffer from major reductions in quality of life and
poor survival, similar to certain malignancies [4]. A re-
duced forced vital capacity (FVC) has been shown to be
the most reliable risk factor for disease progression [5,
6]; indeed, in IPF a FVC decline of 5–10% over 6 months
is associated with an increased risk of mortality [6].
In addition to variation in the disease course between
patients with fibrotic ILD, disease-related symptoms can
be highly variable within a patient. An acute respiratory
deterioration is for example seen in the event of an acute
exacerbation [7, 8], which has been reported to have a
one-year incidence of 3.3–11.5% in non-IPF ILD [9, 10],
and 14.2–19.0% in advanced IPF [7, 11]. Importantly,
acute exacerbations are associated with an increased
mortality risk in IPF and non-IPF ILD [8]. As a conse-
quence of the variable respiratory status, hospital-based
pulmonary function tests, which are usually performed
every three to six months as part of the routine care of
ILD, may not fully capture the extent of the disease. It
has been shown that in patients with IPF, daily domicil-
iary spirometry to measure FVC can be highly clinically
informative by potentially helping to detect patients at
risk for acute exacerbations, or to monitor the effective-
ness of novel therapies [12, 13]. In addition, daily domi-
ciliary spirometry offers the opportunity for a more
detailed insight into FVC-changes, and of potential dis-
ease progression. For example, in lung transplantation
recipients, daily spirometry can identify patients with
rapid deterioration, especially those at increased mortal-
ity risk [14].
Recently, home spirometry was included in a random-
ized controlled phase II study with fibrotic unclassifiable
ILD [15]. Furthermore, the usefulness of home spirom-
etry was studied in ten patients with sarcoidosis and
showed good feasibility [16]. Another very recently pub-
lished study investigated diurnal variations in FVC using
home spirometry in patients with different fibrotic ILDs
[17]. Beyond that, home spirometry has not been studied
in ILD other than IPF, so far, and literature on home
spirometry is still limited. Therefore, the aim of this
study was to determine feasibility in different types of fi-
brotic non-IPF ILD and investigate the clinical impact of
daily home spirometry in patients with progressive ILD
with respect to disease progression.
Methods
Study patients
Individuals with a consensus diagnosis of fibrotic ILD
(IPF or non-IPF) [18–20], and subjective clinical pro-
gression were recruited from May 2017 until August
2018 in the in- and out-patient unit of the Department
of Internal Medicine V of the University of Munich.
Subjective clinical progression was defined as an increase
of dyspnea and/or physical limitations within the last
six months. Patients with pulmonary obstruction (forced
expiratory volume in 1 s < 70%) were not included. This
study was conducted in accordance with the amended
Declaration of Helsinki. Our study was approved by the
local ethics committee of the University of Munich (UE
No. 812–16) and all participants provided signed, in-
formed consent. Patients were followed for six months,
or until death or lung transplantation.
Study design
Patients were asked to perform daily home spirometry
for six months. Hospital-based lung function testing
(comprising spirometry, plethysmography and gas trans-
fer), 6-min walking distance, and clinical assessments
were performed at baseline, after three and six months.
Subjects were also asked to fill out the St. George’s Re-
spiratory Questionnaire (SGRQ), the King’s Brief Inter-
stitial Lung Disease (K-BILD) questionnaire and a 10 cm
visual analogue scale (VAS) for cough [21–24].
Spirometry
Study participants were provided with the hand-held
spirometer mySpiroSense® (PARI GmbH, Starnberg,
Munich), which conforms with international standards
[25]. The spirometer measures FVC by means of a tur-
bine volume transducer and provides a digital read out
registered in litres at pressure saturated water vapor
(BTPS) and body temperature. Patients received 30min
of instruction on how to perform spirometry, which was
repeated at the three month visit. The individual base-
line reference values were obtained by using the best
FVC from three technically adequate, supervised forced
expiratory maneuvers with mySpiroSense® after patients
had demonstrated acceptable technique [25]. Patients
were asked to perform, if possible, three spirometry ma-
neuvers at approximately the same time of the day every
day, with the best value for each day used for further
analysis. Patients were unblinded for their own home
spirometry results (digital display). Data were recorded
on the spirometer and read out and documented
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electronically at the three and six month hospital visit.
Flow-volume curves were also documented by the spirom-
eter and reviewed to ensure validity. The quality of mea-
surements was assessed based on these flow-volume curves
and only measurements with good quality flow-volume
curves were included in the study. Adherence was calcu-
lated as the number of days with home readings divided by
the days enrolled in the study, as described before [13].
Statistical analysis
Continuous variables are presented as the mean ± stand-
ard deviation (SD), with categorical variables summa-
rized by frequency and percentage. The Wilcoxon rank
sum test was used to compare continuous variables, with
chi square tests or fisher’s exact tests used to compare
categorial variables. Bland-Altman plots were used to
compare hospital-based and home spirometry. Pearson’s
correlation coefficient was used to correlate hospital
spirometry and home spirometry. The hospital-based
FVC value was compared to the mean of seven home
spirometry FVCs from the respective week at baseline,
three months and six months [12, 26]. Individual FVC
variability was calculated using the coefficient of vari-
ation (CoV) of all home spirometry values within the
first 28 days. Additionally, taking potential disease pro-
gression into account, individual FVC variability was
analysed over three months using the CoV with
detrended data points by fitting a linear regression
model on individual patients FVC over time and sub-
tracting the residuals, as described before [26]. Pearson
correlation was used to compare FVC CoV of the first
28 days, the following 28 days and the 28 days following
the three months visit. A linear regression model was
applied using only available values without imputation
to calculate individual FVC slopes measured by home
spirometry or hospital-based spirometry. Slopes of home
and hospital-based spirometry were analysed using the
pearson’s correlation coefficient. Disease progression
was defined as death due to respiratory failure, lung
transplantation, acute exacerbation or hospital-based
FVC decline > 10% relative at the three or six months
visit. Cox proportional hazard regression analysis was
applied to identify associations of FVC variability and
disease progression including the covariates baseline
FVC, age and gender. The R-function “ctree” of the
package “party” was used to define a cutoff value of FVC
CoV for survival analysis. The Kaplan–Meier method
was used to evaluate progression- and transplant-free
survival time in the study population, with a log-rank
test used to analyse differences between groups. P values
< 0.05 were considered statistically significant. Data were
analysed using SPSS version 25.0 (IBM SPSS, Armonk,
NY) or GraphPad Prism version 8.0 for Mac (GraphPad
Software, San Diego, California).
Results
Study cohort
Of 74 patients, who were screened for eligibility for the
study from May 2017 until August 2018, 47 patients
(IPF n = 20; non-IPF n = 27) were included in the study
as depicted in Fig. 1. Non-IPF patients had connective
tissue disease-related ILD (n = 10), chronic hypersensi-
tivity pneumonitis (n = 7), unclassifiable ILD (n = 6) or
non-specific idiopathic pneumonia (n = 4). The IPF co-
hort was more likely to be male than the non-IPF cohort
(80.0% vs. 44.4%; p = 0.014), and was older (67.7 ± 7.2
years vs. 59.0 ± 12.7 years; p = 0.009) (Table 1). The over-
all mean ± SD FVC was 63.8 ± 20.9% predicted (2.3 ± 0.8
L), and did not differ between IPF and non-IPF patients.
During the study, the majority of patients received med-
ical treatment (IPF 75.0% antifibrotic therapy; non-IPF:
66.7% immunosuppressive therapy).
Acceptance, adherence and validity of daily home
spirometry
Acceptance of home spirometry was high, with only four
patients (8.5%; IPF: n = 2; non-IPF n = 2) discontinuing
within the first week as they were unable to perform
daily measurements due to dyspnea. In comparison to
the remaining 43 patients, the patients who were not
able to perform daily spirometry were significantly older
(72.3 ± 7.0 years vs. 61.3 ± 11.4 years; p = 0.042). One pa-
tient had technical problems with the spirometer within
the first 28 days and in two patients more than 50% of
the measurements were of poor quality and had to be
excluded. Therefore, only 40 patients were included in
further analyses (≥50% of measurements in the first
4 weeks). These 40 patients participated for a mean ± SD
of 161 ± 38 days (min 28; max 231 days) in the study,
performing home spirometry measurements on a mean
of 81.8 ± 18.4% days and 98.4 ± 3.5% of these measure-
ments were of good quality. As shown in Figs. 1, 34 pa-
tients completed the full set of six months home
spirometry. In these patients, adherence was higher
within the first three months compared to the second
three months (83.5 ± 19.6% vs. 78.4 ± 22.3% of the days;
p = 0.0086) and did not correlate with patients’ age.
There was a strong correlation between the baseline
hospital FVC value, and the mean of the home FVC
measurements over the first seven days (r = 0.96; p <
0.0001), as well as good overall agreement (bias 0.057 L;
95% limits of agreement − 0.42 to 0.53 L; Fig. 2). The
correlation between hospital FVC values and the mean
of the home FVC measurements was similarly strong at
the three months (r = 0.95; p < 0.0001) and six months
visit (r = 0.93; p < 0.0001).
A full set of six months home and hospital spirometry
was available in 34 patients. Using linear regression ana-
lysis, the mean ± SD change in FVC in these patients
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Fig. 1 Study cohort. Abbreviations: IPF, idiopathic pulmonary fibrosis; ILD, interstitial lung disease; CTD-ILD, connective tissue disease-related
interstitial lung disease; HP, hypersensitivity pneumonitis; uILD, unclassifiable interstitial lung disease; NSIP, non-specific idiopathic pneumonia







Age (years) 62.7 ± 11.5 67.7 ± 7.2 59.0 ± 12.7
Gender, male (%) 28 (59.6) 16 (80.0) 12 (44.4)
BMI (kg/m2) 27.0 ± 4.5 26.8 ± 4.7 27.2 ± 4.5
Smoking status
Ex-smoker 24 (51.1) 14 (70.0) 10 (37.0)
Pack years 25.9 ± 20.5 29.6 ± 23.2 20.6 ± 15.6
Lung function
FVC, % predicted 63.8 ± 20.9 65.6 ± 19.1 62.5 ± 22.4
FVC (L) 2.3 ± 0.8 2.5 ± 0.8 2.2 ± 0.8
TLC, % predicted 69.2 ± 18.8 68.3 ± 16.9 69.9 ± 20.5
TLC (L) 4.2 ± 1.1 4.4 ± 1.2 4.1 ± 1.0
DLCO, % predicteda 37.8 ± 15.6 34.5 ± 15.4 40.1 ± 15.7
6MWD (m)b 380 ± 121 405 ± 107 364 ± 129
K-BILD 53.2 ± 11.4 50.6 ± 10.6 55.1 ± 11.9
SGRQc 51.5 ± 18.2 57.6 ± 13.0 47.1 ± 20.3
VAS cough (cm) 3.3 ± 2.6 3.8 ± 2.7 2.8 ± 2.4
Data are presented as mean ± standard deviation or number (percentage).
Definition of abbreviations: 6MWD 6-min walk distance, BMI body mass index,
DLCO diffusion capacity for carbon monoxide, FVC forced vital capacity, K-BILD
King’s Brief Interstitial Lung Disease, SGRQ St George’s Respiratory
Questionnaire, TLC total lung capacity, VAS visual analogue scale
a n = 30 patients (IPF: n = 13; non-IPF: n = 17). b n = 41 patients (IPF: n = 16;
non-IPF: n = 25). c n = 43 patients (IPF: n = 18; non-IPF: n = 25)
Fig. 2 Bland-Altman plot comparing hospital FVC at baseline and
home spirometry. Hospital FVC was obtained at the baseline visit;
values for home-based FVC are the individual mean of all daily
readings within the first seven days of home spirometry. Dashed
lines represent the 95% limits of agreement
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was − 135.1 ± 303.7 mL (range − 1074.7 to 336.4 mL)
measured by home spirometry and − 72.4 ± 227.1 ml
(range − 672.1 to 424.0 mL) measured by hospital-based
spirometry. The FVC slopes of home and hospital-based
spirometry showed a moderate correlation (r = 0.441;
p = 0.009).
Daily FVC variability
During the study, 12 patients (30.0%; IPF: n = 5; non-IPF
n = 7) had a progression of ILD. Examples of individual
FVC courses are shown in Fig. 3. Reasons for disease
progression were death (n = 2), lung transplantation (n =
3 [lung transplantation following acute exacerbation n =
2, lung transplantation following FVC decline > 25%: n =
1]), acute exacerbation (n = 1) and hospital-based FVC
decline > 10% (n = 6 [FVC decline > 10% at three month
visit: n = 2; FVC decline > 10% at six month visit n = 4]).
Of the five IPF patients with disease progression, 80.0%
(n = 4) were treated with antifibrotic therapy, of the seven
patients with non-IPF, 71.4% (n = 5) had an immunosup-
pressive therapy at the time of the study. Although at
baseline there were no significant differences in age, FVC
% predicted, DLCO, SGRQ or VAS cough between pa-
tients with progressive vs. stable disease, the 6MWD
(301 ± 140m vs. 433 ± 89m; p = 0.009) and the K-BILD
total score (46.3 ± 8.1 vs. 55.8 ± 12.7; p = 0.004) were
clearly lower in the progressive group, indicating more
physical and subjective wellbeing limitations (Table 2).
However, a group of patients had high variability in
daily FVC. In the first 28 days (adherence 90.3 ± 12.0%),
60.0% of the patients had FVC CoV ≥5 and 15.0% had
FVC CoV ≥10% (Fig. 4). The median of all individual
FVC CoVs was 5.9%, ranging from 3.5 to 17.8%. The ex-
tent of variation differed clearly between the progressive
and stable groups: The median FVC CoV was 8.6% (min
3.5%, max 17.8%) in the progressive group and 4.8%
(min 3.5%, max 13.9%) in the stable group (Fig. 5; p =
0.002). There was no relationship between CoV and
underlying ILD disease entity. Further, the FVC CoV did
not differ between patients treated and not treated with
antifibrotic therapy (p = 0.91).
To evaluate reproducibility and the potential influence
of learning effects on FVC variability, a correlation ana-
lysis was performed which showed a strong correlation
between the FVC CoV of the first 28 days and the fol-
lowing 28 days (r = 0.79; p < 0.001), as well as a strong
correlation between the FVC CoV of the first 28 days
and the 28 days following the three months visit (r =
0.82; p < 0.001). There was no significant difference be-
tween the mean ± SD FVC CoV of the first 28 days and
the following 28 days (first 28 days: 6.7 ± 3.3; following
28 days: 6.1 ± 3.0; p = 0.40). In patients, for whom the
Fig. 3 Individual FVC courses in patients with ILD. a Patient with
non-IPF ILD, who died at day 128. b Patient with IPF and FVC
decline of 15% relative over six months. c Patient with non-IPF ILD
and stable lung function









Age (years) 60.7 ± 11.3 59.6 ± 12.6 63.1 ± 7.6 0.59
FVC, % predicted 64.7 ± 21.7 67.1 ± 21.9 59.2 ± 21.1 0.31
DLCO, % predicteda 41.2 ± 19.7 43.1 ± 21.3 36.3 ± 18.4 0.33
6MWD (m)b 390 ± 123 433 ± 89 301 ± 140 0.009
SGRQc 52.8 ± 18.9 55.2 ± 19.4 48.0 ± 17.7 0.18
K-BILD 52.9 ± 12.2 55.8 ± 12.7 46.3 ± 8.1 0.004
VAS cough 3.3 ± 2.6 2.8 ± 2.5 4.4 ± 2.5 0.06
Data are presented as mean ± standard deviation. Definition of abbreviations:
6MWD 6-min walk distance, DLCO diffusion capacity for carbon monoxide, FVC
forced vital capacity, K-BILD King’s Brief Interstitial Lung Disease, SGRQ St
George’s Respiratory Questionnaire, VAS visual analog scale
a n = 26 patients (stable: n = 19; progressive: n = 7); b n = 34 patients (stable:
n = 23; progressive: n = 11); c n = 37 patients (stable: n = 25;
progressive: n = 12);
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FVC CoV following the three months visit was available
(n = 34), there was also no significant difference between
the FVC CoV in the first 28 days and the CoV following
the three months visit (first 28 days: 6.5 ± 3.3; 28 days
following three months visit: 6.2 ± 2.9; p = 0.63). Further-
more, to assure that variability was not driven by short-
term lung function deterioration, the FVC CoV and the
slope of FVC within the first 28 days were correlated and
showed no relationship (r = − 0.26; p = 0.11).
To assess whether FVC variability can also be ob-
served over a longer observation period, the CoV was
further analysed over three months with detrended data
points. FVC variability over three months showed a
strong correlation with the FVC variability over 28 days
(r = 0.936; p < 0.001). Also, over three months, patients
with disease progression had significantly higher FVC
variability compared to stable patients (8.4 ± 3.2% vs.
5.5 ± 2.5%; p = 0.002).
To see whether patients with disease progression had
also higher FVC variability in hospital-based spirometry
we further analysed the 34 patients, who had a full set of
six months home and hospital spirometry. Of these,
seven had a disease progression. The CoV with
detrended data points of the three hospital FVCs (base-
line, three months and six months) did not significantly
differ between the progressive and the stable patients
(4.2 ± 3.9% vs. 2.6 ± 2.8%; p = 0.391).
Disease progression
FVC variability over 28 days was independently associated
with disease progression (HR 1.203; 95% CI: 1.050–1.378;
p = 0.0076) while the covariates baseline FVC, age and
gender were no significant predictors in the regression
analysis in this cohort (Table 3). The optimal cutoff to dif-
ferentiate between patients with low and high variability
was found to be 7.9%. A progress of ILD was found in
14.3% (n = 4) of the patients with low variability (< 7.9%
rel.) and in 66.7% (n = 8) of the patients with high variabil-
ity (≥7.9% rel.). In the Kaplan-Meier survival analysis,
while the six months progression- and transplant-free sur-
vival rate was 77.2% in patients with low variability (< 7.9%
rel.), it was 37.5% in patients with high variability (≥7.9%
rel.; p = 0.003; Fig. 6). FVC variability over three months
Fig. 4 Different variability of daily FVC among representative patients
within 28 days. a Patient with low variability in FVC (3.7% FVC CoV). b
Patient with high variability in FVC (11.9% FVC CoV)
Fig. 5 FVC variability in patients with stable and progressive disease.
Progressive patients showed a significantly higher FVC variability
within the first 28 days of home spirometry in comparison to stable
patients (p = 0.002)
Table 3 Cox proportional hazard regression analysis assessing
the effect on disease progression
Hazard Ratio 95%-CI p-value
Age 1.036 0.951–1.130 0.416
gender 0.655 0.160–2.682 0.556
Baseline FVC, % predicted 0.997 0.954–1.041 0.876
FVC variability 1.203 1.050–1.378 0.0076
FVC variability was assessed over 28 days
Definition of abbreviations: CI confidence interval, FVC forced vital capacity
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was also a significant predictor for disease progression in
the regression analysis with the covariates baseline FVC, age
and gender (HR: 1.290; 95%-CI: 1.013–1.643; p = 0.039).
Discussion
The clinical course of ILD can be highly variable, and
given the unfavorable prognosis of progressive, fibrotic
ILD, it is important to identify predictive factors. Re-
cently, it has been shown that daily home spirometry
can provide important information about the clinical
course in patients with IPF [12]. However, studies on the
usefulness in non-IPF ILD are still limited. Our study fo-
cused on home spirometry in patients with IPF and vari-
ous fibrotic non-IPF ILD, and showed that over
one month, FVC can vary greatly in these patients. Fur-
thermore, we demonstrated in the present study that
FVC variability was associated with disease progression.
Daily home spirometry had a high degree of acceptance,
although 8.5% of patients struggled with daily spirometry
due to dyspnea and 6.4% had technical problems or poor
quality of measurements.
While hospital-based pulmonary function tests cannot
be performed on a daily basis, home spirometry allows us
to get a more frequent and deeper insight into the respira-
tory status of our patients, including FVC variability. As
shown earlier, the phenomenon of daily spirometric vari-
ability seems to occur more often in patients with lung
disease than in healthy controls [27]. Recently, daily FVC
variability has also been shown in fibrotic ILDs [17]. The
authors of this study identified a diurnal variation with
higher FVC values in the morning compared to the after-
noon. In line with our observations, two other studies de-
scribed FVC variability of 0.04 to 0.39 L over 28 days of
home spirometry in patients with IPF [12, 28]. Indeed,
these analyses were only used to evaluate within-subject
reproducibility of measurements and were not analysed
for their correlation with disease progression [12, 28].
Johannson et al. also observed high variability in FVC in
patients with IPF [13], although with home spirometry
performed on a weekly basis, and again, variability was not
studied in relation to clinical outcome. Interestingly, Rus-
sell et al. described a CoV of FVC of 4.96% (range 2.06–
20.9%) in IPF patients, which matches our findings [12].
As FVC variability could potentially be caused by factors
like spirometry technique (including learning effects),
cough, disease progression, mucus production or infection
we assessed the relationship between CoV of the first 28
days and the CoV of the second 28 days as well as the
CoV of the 28 days following the three months visit and
identified a good individual reproducibility. Although the
FVC CoV was slightly higher within the first 28 days in com-
parison to the following 28 days and the 28 days following
the three months visit, these differences were not significant.
Therefore, in our study, the influence of learning effects
(spirometry technique) on the FVC variability appears to be
small. Moreover, there was no relationship between CoV
and deterioration of lung function within 28 days. Interest-
ingly, our finding that increased variability is associated with
disease progression holds true when the variability is assessed
over an extended period of time using the CoV over three
months with detrended data points [26].
Our results raise the question of whether FVC variabil-
ity might be a previously unknown predictor for disease
progression. In fact, in the past, it has been shown sev-
eral times that baseline FVC is the most reliable pre-
dictor of progression in IPF [5, 6, 29–31]. In our study,
however, FVC variability was the only significant pre-
dictor for ILD disease progression. It should be noted,
that for a major effect of other variables (e.g. baseline
FVC) the patient number in our study may have been
too small. The observed FVC variability could be inter-
preted as representation of recurrent subclinical FVC
Fig. 6 Progression- and transplant-free survival in patients with low and high FVC variability. Based on the optimal cut-off of 7.9%, patients with
high FVC variability (≥7.9%) had significantly shorter progression- and transplant-free survival compared to patients with low FVC variability
(< 7.9%; p = 0.003)
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deterioration. We speculate that in a diseased lung, such
as ILD, with physiological changes, respiratory capacity
can vary on a daily basis as a sign of a vulnerable lung.
In chronic diseases with limited mobility, such as ad-
vanced ILD, more frequent doctor appointments with
pulmonary function tests are often not feasible. Detect-
ing patients at risk for disease progression might allow
us to monitor or initiate new medical therapies earlier or
evaluate patients for lung transplantation. This further
emphasizes the potential utility of domiciliary spirometry
in ILD, especially with respect to clinical decision mak-
ing. In the future, telemedicine will play an important
role in patient care. Recently, a pilot study investigated
real-time wireless home spirometry in IPF and found it
feasible [28].
An important challenge in the future is that adherence
to home spirometry among our patients decreased sig-
nificantly over time. While the median adherence within
the first 28 days was 90%, over six months this dropped
to 81%. Interestingly, this was not influenced by a small
number of patients with very poor adherence, since at
the end of the study, only 41% still had an adherence of
> 90%. Of note, our spirometer did not include any pro-
grammed reminders which might have had a positive in-
fluence. Nevertheless, the phenomenon of decreasing
adherence occurs even with only weekly measurements
[13]. Currently, however, parameters like FVC variability
can only be assessed through home spirometry. There-
fore, tools have to be developed to minimize barriers
and motivate patients to perform FVC measurements on
a regular basis, as provided by Moor et al. [28]. Further-
more, as a possible outlook for the future, in clinical
practice, it might be sufficient to do daily domiciliary as-
sessments for a limited period of time (for example after
diagnosis or one month per year) as part of standard
care. Finally, a significant challenge in the future is the
interpretation of FVC slopes derived from home spirom-
etry over an extended period of time, for example in
clinical trials. In our study, slopes of home and hospital
spirometry showed a moderate correlation. Overall,
home spirometry detected greater changes in FVC than
hospital spirometry. In 2019, the data of a large phase II
trial with progressive unclassifiable ILD were published,
where the mean change in FVC measured by home spir-
ometry was the primary endpoint [15]. Unfortunately,
due to technical problems and physiologically implaus-
ible measurements, the data of the primary endpoint
could not be sufficiently analysed. Therefore, Maher
et al. clearly stated, that further assessments are re-
quired, before home spirometry can be used regularly in
clinical trials [15]. Very recently data of a randomized
controlled trial investigating the benefit of a home moni-
toring program in terms of improved health related
quality of life and medication use for patients with IPF
was published [26]. In this study by Moor et al. home
spirometry was used, including automated e-mail re-
minders when spirometry was not performed. Over
six months, the authors showed a high adherence rate
to home spirometry and comparable slopes of home
and hospital spirometry. Given these positive results,
programmed reminders and real-time feedback indeed
might be a helpful tool in the future to improve qual-
ity of home spirometry measurements.
The results of our study should be interpreted in
view of the study design and its limitations, which in-
clude a single-centre setting and a limited number of
patients. The small number of patients included in
the study makes it difficult to draw definitive conclu-
sions at this point. Our observations on FVC variabil-
ity must therefore be interpreted rather as hypothesis-
generating and still require validation in separate
(multi-centric) studies in the future. Nevertheless, the
results of our study should be considered relevant
and important as this is the first study to identify
daily FVC variability as a potential prognostic factor
in ILD. Furthermore, not all patients were able to
perform daily spirometry due to dyspnea. Still, this
was a real-life experience and our study was designed
to include patients with progressive ILD, who pre-
sumably would have a high dyspnea burden – and
despite this, there was a high level of acceptability of
daily spirometry. In line with this finding, in another
IPF cohort 13% of patients were unable to perform
home spirometry [13]. However, our study does sug-
gest that home spirometry may not be feasible in all
patients with ILD.
Conclusion
In conclusion, we demonstrated that in ILD, FVC can
vary greatly on a daily basis. Moreover, higher FVC vari-
ability was associated with disease progression in ILD.
Although home spirometry was feasible and accepted in
the majority of patients, daily use can be challenging and
might not be feasible for all patients in the long term.
Nonetheless, home spirometry (even when performed
over a limited period) could help to detect patients at
risk of disease progression, and so might be beneficial
for clinical decision making and in ILD research in the
future. Future studies are needed to further determine
the role of FVC variability and to evaluate whether it
can be used as a biomarker of disease progression in pa-
tients with fibrotic ILD.
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